Hutchmed price target lowered to $21 from $22 at BofA

Core Viewpoint - BofA analyst Alec Stranahan has lowered the price target for Hutchmed (HCM) to $21 from $22 while maintaining a Buy rating on the shares, indicating a cautious but optimistic outlook for the company [1] Group 1: Financial Performance - Hutchmed's FY25 financial results showed some positive developments following a weaker first half of the year [1] Group 2: Future Prospects - The firm expressed confidence in Hutchmed's ability to meet its 2026 guidance for Oncology/Immunology, supported by positive commentary regarding the expansion of fruquintinib indications in 2026 and the increase in the number of Fruzaqla markets [1]